Agilent Technologies is having its best week in years — and the analyst community is scrambling to keep up.
The stock delivered a stunning 17.6% jump on May 28, the morning after its quarterly results, closing out the week up 17.4% at $135.05. That single-day move was the catalyst the recovery bulls had been waiting for. The previous trader note from May 27 framed the print as the "make-or-break moment" — and by that standard, it broke decisively in the bulls' favour. The stock had spent most of 2026 languishing below $120; it now trades well above every target that was set during the long sequence of analyst cuts through February and April.
The analyst response has been swift and broadly constructive. B of A Securities made the most striking move: upgrading to Buy from Neutral on May 28 — the day of the gap — and then, just days later, raising its target further to $155 from the post-upgrade level of $145. RBC Capital, which initiated at Outperform with a $153 target on May 27, lifted that to $155 on May 28. TD Cowen and Barclays both raised targets on earnings day as well, to $155 and $145 respectively. The outlier is HSBC, which maintained its Buy rating but cut its target to $165 from $180 today — a signal that at least one firm sees the post-earnings re-rating as having overshot somewhat. Wolfe Research assumed coverage at Peer Perform, adding a cautious voice at the margin. The mean analyst target now sits at roughly $162, which implies only modest additional upside from current levels after the stock's sharp move — a notably tighter gap than the ~40% discount that existed before the print.
The borrow and positioning picture tells a calmer story. Short interest rose around 14.6% week-on-week in share terms, reaching 1.95% of the free float — still low in absolute terms, but the fastest weekly build in months. Some of that increase may reflect fresh shorts testing the post-earnings high rather than entrenched bears. Borrow remains extremely cheap at 0.33% annualised, down 24% on the week, and availability is essentially uncapped — the lending pool holds over 280 million shares against just 5.5 million short, leaving the borrow market far too loose for any squeeze dynamic to develop. Options positioning is mildly more defensive than usual: the put/call ratio of 0.86 runs slightly above its 20-day average of 0.81, a z-score of 0.69, but well within normal range and nowhere near the elevated readings that would signal genuine hedging pressure.
Among correlated peers, the week's moves put Agilent's gain in sharp relief. BRKR posted a comparable 22% surge — likely its own earnings-driven event — while WAT added a solid 9.8% and AVTR gained 10.4%. The broader life sciences tools group clearly benefited from positive sector sentiment, but Agilent's move was at the top of the range. TMO and DHR were more restrained, up 7.6% and 1.9% respectively, suggesting the gains were not purely macro-driven — Agilent's result carried company-specific weight.
Factor scores offer some nuance. The analyst recommendation differential score ranks in the 97th percentile, reflecting how far consensus sentiment has shifted relative to the broader universe. EPS momentum scores are solid at the 60th–61st percentile over both 30-day and 90-day windows. The short score of 31 is modest and stable, consistent with the limited bearish positioning. What's worth monitoring now is whether the consensus target cluster in the $145–$165 range acts as a ceiling — several firms that raised targets post-earnings are already within striking distance of their new numbers, which historically narrows the margin for further upward revisions unless the fundamental trajectory continues to improve.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
